Nefopam
Based on 3 publication(s) in Google Scholar
Nefopam (Fenazoxine) is an orally active, non-opioid and non-steroidal centrally acting analgesic agent. Nefopam blocks voltage-sensitive sodium channels (IC50=27 μM) and modulates glutamatergic transmission in rodents. Nefopam can be used in studies of neuropathic pain, anticonvulsant, as well as the prevention of postoperative shivering and hiccups.
For research use only. We do not sell to patients.
- CAS No.: 13669-70-0
- Formula: C17H19NO
- Molecular Weight:253.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Nefopam
More
Biological Activity
Nefopam (0.1-100 μM; 15 min) inhibits the uptake of 22Na in a concentration-dependent manner in SK-N-SH cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SK-N-SH cells
-
Concentration:0.1-100 µM
-
Incubation Time:15 min (preincubate)
-
Result:Inhibited the uptake of 22Na with an IC50 value of 27 µM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male NMRI mice (25-30 g; 6 to7-week-old; electroshock-induced seizures model)[1]
-
Dosage:0-10 mg/kg
-
Administration:Intravenous injection; single
-
Result:Produced dose-dependent protection against maximal electroshock seizures in mice with an ED50 of 3.8 (2.9-5.1) mg/kg.
-
Animal Model:Adult male mice (10-week-old; 25-30 g; vincristine-induced peripheral neuropathy model)[2].
-
Dosage:10, 30, 60 mg/kg
-
Administration:Intraperitoneal injection; single
-
Result:Significantly decreased the percentage of NK1 receptors in the spinal cord at dosage of 60 mg/kg.
Showed a sustained increase in paw withdrawal threshold against mechanical stimuli.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 13669-70-0
-
Molecular Weight 253.34
-
Formula C17H19NO
-
SMILES
CN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3C1
-
Synonyms
Fenazoxine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
ACS Omega
2020 Oct 12;5(41):26551-26561. PMID: 33110983 -
Sci Rep
2019 Jun 21;9(1):9005. PMID: 31227757 -
Mol Carcinog
KDM6A Exhibits Antitumor Activities Toward Ovarian Cancer by Epigenetically Activating Transcription of ISG-15. [Abstract]2025 Nov 18. PMID: 41252674
Purity & Documentation
References
[1]. Verleye M, et al. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res. 2004 Jul 9;1013(2):249-55. [Content Brief]
[2]. Lee JY, et al. The Antiallodynic Effect of Nefopam on Vincristine-Induced Neuropathy in Mice. J Pain Res. 2020 Feb 7;13:323-329. [Content Brief]
[3]. Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Nefopam Related Classifications
HY-133195 Related Classifications
Powered by Bioz